JP2022538076A5 - - Google Patents

Info

Publication number
JP2022538076A5
JP2022538076A5 JP2021576253A JP2021576253A JP2022538076A5 JP 2022538076 A5 JP2022538076 A5 JP 2022538076A5 JP 2021576253 A JP2021576253 A JP 2021576253A JP 2021576253 A JP2021576253 A JP 2021576253A JP 2022538076 A5 JP2022538076 A5 JP 2022538076A5
Authority
JP
Japan
Prior art keywords
cancer
crystalline form
diffraction peaks
fumarate
characteristic diffraction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021576253A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022538076A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2020/097482 external-priority patent/WO2020253875A1/zh
Publication of JP2022538076A publication Critical patent/JP2022538076A/ja
Publication of JP2022538076A5 publication Critical patent/JP2022538076A5/ja
Pending legal-status Critical Current

Links

JP2021576253A 2019-06-21 2020-06-22 化合物の塩、塩の結晶形体およびその製造方法と使用 Pending JP2022538076A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910542355 2019-06-21
CN201910542355.6 2019-06-21
PCT/CN2020/097482 WO2020253875A1 (zh) 2019-06-21 2020-06-22 一种化合物的盐、其晶型以及制备方法与应用

Publications (2)

Publication Number Publication Date
JP2022538076A JP2022538076A (ja) 2022-08-31
JP2022538076A5 true JP2022538076A5 (enExample) 2023-06-28

Family

ID=74040655

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021576253A Pending JP2022538076A (ja) 2019-06-21 2020-06-22 化合物の塩、塩の結晶形体およびその製造方法と使用

Country Status (16)

Country Link
US (1) US20220168302A1 (enExample)
EP (1) EP3988546A4 (enExample)
JP (1) JP2022538076A (enExample)
KR (1) KR20220041090A (enExample)
CN (1) CN115708409A (enExample)
AR (1) AR119184A1 (enExample)
AU (1) AU2020296048A1 (enExample)
BR (1) BR112021025944A2 (enExample)
CA (1) CA3144546A1 (enExample)
CL (1) CL2021003438A1 (enExample)
CO (1) CO2022000502A2 (enExample)
IL (1) IL289231A (enExample)
MX (1) MX2022000051A (enExample)
PH (1) PH12021553151A1 (enExample)
WO (1) WO2020253875A1 (enExample)
ZA (1) ZA202200964B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022042738A1 (zh) * 2020-08-31 2022-03-03 甘李药业股份有限公司 一种含cdk4/6抑制剂的药物组合物
US20250332167A1 (en) * 2021-05-17 2025-10-30 Gan & Lee Pharmaceuticals Co., Ltd. Pharmaceutical use of cdk 4/6 inhibitor
EP4696689A1 (en) * 2023-04-04 2026-02-18 Suzhou Kintor Pharmaceuticals, Inc. Salt form and crystal form of chiral heterocyclic compound having hedgehog pathway antagonist activity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK9742002A3 (en) * 2000-01-07 2003-02-04 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
CN106810536A (zh) * 2015-11-30 2017-06-09 甘李药业股份有限公司 一种蛋白激酶抑制剂及其制备方法和医药用途

Similar Documents

Publication Publication Date Title
AU2015292425B2 (en) 2-H-indazole derivatives as cyclin-dependent kinase (CDK) inhibitors and therapeutic uses thereof
ES2670416T3 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento de cáncer
JP5207386B2 (ja) ピリミジン−2,4−ジアミンおよびその使用
JP4740878B2 (ja) キナーゼインヒビターとしてのピロロトリアジン化合物
CA3188077A1 (en) Egfr inhibitor, preparation method therefor and application thereof
JP2022513971A (ja) Kif18a阻害剤として有用なヘテロアリールアミド
EP3746072B1 (en) 2h-indazole derivatives as cdk4 and cdk6 inhibitors and therapeutic uses thereof
CA3098336A1 (en) Crystal form of c-met inhibitor and salt form thereof and preparation method therefor
CA2974788C (en) A 2-pyrimidinyl substituted pyridinyl heterocyclic compound and a pharmaceutical composition comprising the same
AU2016328692B2 (en) New compounds
EP3373932B1 (en) Crystalline form of a substituted quinoline compound and pharmaceutical compositions thereof
AU2019316858B2 (en) Smad3 inhibitors
CN104507944A (zh) 作为fgfr抑制剂的蝶啶
JP2010520187A (ja) 新規ピリミジン誘導体
JP7790746B2 (ja) ヘテロアリール誘導体、そのヘテロアリール誘導体の調製方法、及びそのヘテロアリール誘導体を活性成分として含む医薬組成物
CN115708409A (zh) 一种化合物的盐、其晶型以及制备方法与应用
CN108047205B (zh) 2-(2,4,5-取代苯氨基)嘧啶衍生物、其制备方法及其在制备抗肿瘤药物中的应用
WO2025214350A1 (en) Macrocyclic compounds as ras inhibitors for the treatment of cancer
TW200530187A (en) 3-cyano-quinoline derivatives with antiproliferative activity
WO2022262691A1 (en) Heterocyclic compounds as sos1 inhibitors
US20250345339A1 (en) Doses and regimens of her2 inhibitors
CN109593102A (zh) 一种氘代二苯氨基嘧啶类化合物的制备方法及其晶型
CN107108633A (zh) 作为PI3Kβ抑制剂的杂环基连接的咪唑并哒嗪衍生物
AU2016328693B2 (en) Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
JP2025501305A (ja) ヘテロ芳香族窒素酸化物化合物、その調製方法及びその使用